Cocoon Trial Protocol Halves Skin Toxicities In Lung Cancer Treatment

A caller investigation position was published in Volume 13 of Oncoscience on March 11, 2026, titled "Early occurrence of nan COCOON trial: Preventing dermatologic adverse events successful first-line EGFR-mutant NSCLC."

Led by first and corresponding writer Bishal Tiwari from the Nassau University Medical Center and Asmita Koirala from the Western Regional Hospital successful Nepal, nan commentary summarizes interim findings from nan shape II COCOON trial, which tested whether a system dermatologic prophylaxis regimen could trim tegument toxicities successful patients receiving first-line amivantamab positive lazertinib.

The commentary describes a prophylactic protocol that included oral doxycycline aliases minocycline, ceramide-based moisturization, chlorhexidine nail care, and topical clindamycin. In nan interim analysis, nan COCOON regimen reduced moderate-to-severe dermatologic adverse events, pinch nan incidence of people ≥2 events falling from 76.5% pinch modular reactive attraction to 38.6% pinch prophylaxis. The insubstantial besides reports reductions successful people ≥3 events and curen discontinuations, underscoring nan applicable worth of proactive supportive attraction for EGFR-mutant non-small compartment lung cancer.

"The COCOON results stress nan objective worth of anticipating EGFR inhibitor-related toxicities done multidisciplinary supportive care."

The authors reason that these results reenforce nan request to merge dermatologic prevention into first-line curen readying for EGFR-mutant NSCLC. They statement that straightforward, low-cost interventions tin amended tolerability and support dose intensity, while early objective believe updates will apt incorporated this benignant of proactive supportive attraction attack much broadly.